Significant amplification or mutation events are observed in pancreatic, colorectal, and lung cancers, with minimal alterations in hematologic malignancies such as AML (Figure S7A, Supporting Information), indicating a potential role for C1r in solid tumor progression. Here, C1R is linked to lung carcinoma.